MARKET NEWS

Orion Biotechnology Reports Positive Results for Preclinical Study
Menlo Therapeutics Granted Breakthrough Therapy Designation
Auris Medical Provides Update on Intranasal Betahistine Programs
First Patient Dosed in Phase 1 Clinical Trial Evaluating Neoepitopes Formulated in IMV’s DPX Delivery Platform
AMAG Pharmaceuticals Completes Acquisition of Perosphere
Zafgen Announces Positive Results for Phase 2 Clinical Trial

  FEATURED EDITORIAL

  COMPANY PROFILE

AbbVie Contract Manufacturing has been serving our partners for more than 35 years across ten of our manufacturing facilities located in both North America and Europe. Our contract development and manufacturing capabilities span both small and large molecule API including classical fermentation, chemical synthesis and biologics. In addition to APIs, we are offering extensive experience and technical solutions in the area of drug product manufacturing which includes traditional tablet and capsule production with emphasis on DEA controlled drugs, potent, ADCs and hot melt extrusion. Lastly, we can also package your product regionally and also offer prefilled syringe manufacturing capabilities. Click here for more.

  EXCLUSIVE ONLINE CONTENT

TrakCel & Quick Partner to Provide Industry-Leading Digital Supply Chain IT Solution for Cell & Gene Therapies

TrakCel & Quick Partner to Provide Industry-Leading Digital Supply Chain IT Solution for Cell & Gene Therapies

TrakCel and The Quick Life Science Group recently announced a partnership to offer an integrated IT logistics orchestration platform. 

MilliporeSigma & Roche Renew Global Distribution Agreement   

MilliporeSigma & Roche Renew Global Distribution Agreement  

MilliporeSigma and Roche recently announced they have agreed to renew their current distribution agreement for the Biochemical Reagents and Kapa Biosystems product portfolios, as well as select qPCR & Nucleic Acid Purification products.

Bavarian Nordic Announces Exercise of -Million Option by BARDA

Bavarian Nordic Announces Exercise of $44-Million Option by BARDA

Bavarian Nordic A/S recently announced the US Biomedical Advanced Research and Development Authority (BARDA) have exercised another option under the ongoing contract for freeze-dried MVA-BN smallpox vaccine.

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

January 30 – Bioavailability
February 6 – Analytical Testing